Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
about
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
description
im September 2018 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 27 September 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2019
@uk
name
Mutations in the RAS-BRAF-MAPK ...... n chronic lymphocytic leukemia
@en
Mutations in the RAS-BRAF-MAPK ...... n chronic lymphocytic leukemia
@nl
type
label
Mutations in the RAS-BRAF-MAPK ...... n chronic lymphocytic leukemia
@en
Mutations in the RAS-BRAF-MAPK ...... n chronic lymphocytic leukemia
@nl
prefLabel
Mutations in the RAS-BRAF-MAPK ...... n chronic lymphocytic leukemia
@en
Mutations in the RAS-BRAF-MAPK ...... n chronic lymphocytic leukemia
@nl
P2093
P50
P1433
P1476
Mutations in the RAS-BRAF-MAPK ...... n chronic lymphocytic leukemia
@en
P2093
Alejandra Martínez-Trillos
Angel R Payer
Armando Lopez-Guillermo
Arnau Montraveta
Blanca Navarro
Dolors Colomer
Elias Campo
Estella Matutes
Laia Rosich
P304
P356
10.3324/HAEMATOL.2018.196931
P407
P50
P577
2018-09-27T00:00:00Z